Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Symbol: 2196.HK

HKSE

13.28

HKD

Market price today

  • 15.5749

    P/E Ratio

  • 7.2266

    PEG Ratio

  • 63.71B

    MRK Cap

  • 0.04%

    DIV Yield

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196-HK) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.47%

Operating Profit Margin

0.07%

Net Profit Margin

0.05%

Return on Assets

0.02%

Return on Equity

0.04%

Return on Capital Employed

0.04%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO:Mr. Deyong Wen
Full-time employees:40370
City:Shanghai
Address:Building A
IPO:2012-10-30
CIK:

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments. The company offers pharmaceutical products in the areas of tumor, immune modulation, metabolism, alimentary and central nervous system. It also provides medical devices and diagnostic products. In addition, the company offers health care and hospital management services. Further, it engages in retail and wholesale distribution of medicines. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.

General Outlook

When we look at how much money they make before expenses, they keep 0.475% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.071%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.049%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.018% return, is a testament to Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s adeptness in optimizing resource deployment. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.044%. Furthermore, the proficiency of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. in capital utilization is underscored by a remarkable 0.036% return on capital employed.

Stock Prices

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $14.4, while its low point bottomed out at $14.04. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s stock market.

Liquidity Ratios

Analyzing 2196.HK liquidity ratios reveals its financial health of the firm. The current ratio of 100.71% gauges short-term asset coverage for liabilities. The quick ratio (69.54%) assesses immediate liquidity, while the cash ratio (38.70%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio100.71%
Quick Ratio69.54%
Cash Ratio38.70%

Profitability Ratios

2196.HK profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 7.12% underscores its earnings before tax deductions. The effective tax rate stands at 11.43%, revealing its tax efficiency. The net income per EBT, 69.32%, and the EBT per EBIT, 99.88%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 7.13%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin7.12%
Effective Tax Rate11.43%
Net Income per EBT69.32%
EBT per EBIT99.88%
EBIT per Revenue7.13%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.01, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding70
Days of Inventory Outstanding125
Operating Cycle199.42
Days of Payables Outstanding105
Cash Conversion Cycle95
Receivables Turnover4.87
Payables Turnover3.49
Inventory Turnover2.93
Fixed Asset Turnover1.90
Asset Turnover0.36

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 1.30, and free cash flow per share, -0.54, depict cash generation on a per-share basis. The cash per share value, 5.67, showcases liquidity position. A payout ratio of 1.23 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.08, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share1.30
Free Cash Flow per Share-0.54
Cash per Share5.67
Payout Ratio1.23
Operating Cash Flow Sales Ratio0.08
Free Cash Flow to Operating Cash Flow Ratio-0.41
Cash Flow Coverage Ratio0.10
Short Term Coverage Ratio0.18
Capital Expenditure Coverage Ratio0.71
Dividend Paid and Capex Coverage Ratio0.47
Dividend Payout Ratio0.06

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 30.69%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.75, we discern the balance between debt and equity financing. The long-term debt to capitalization, 24.69%, and total debt to capitalization, 42.96%, ratios shed light on its capital structure. An interest coverage of 2.09 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio30.69%
Debt Equity Ratio0.75
Long Term Debt to Capitalization24.69%
Total Debt to Capitalization42.96%
Interest Coverage2.09
Cash Flow to Debt Ratio0.10
Company Equity Multiplier2.45

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 15.44, provides a glimpse into top-line earnings distributed across each share. Net income per share, 0.89, reflects the portion of profit attributed to each share. The book value per share, 17.04, represents the net asset value distributed per share, while the tangible book value per share, 10.59, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share15.44
Net Income Per Share0.89
Book Value Per Share17.04
Tangible Book Value Per Share10.59
Shareholders Equity Per Share17.04
Interest Debt Per Share13.59
Capex Per Share-1.99

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -5.81%, indicates top-line expansion, while the gross profit growth, -4.70%, reveals profitability trends. EBIT growth, -60.13%, and operating income growth, -60.13%, offer insights into operational profitability progression. The net income growth, -36.04%, showcases bottom-line expansion, and the EPS growth, -37.76%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-5.81%
Gross Profit Growth-4.70%
EBIT Growth-60.13%
Operating Income Growth-60.13%
Net Income Growth-36.04%
EPS Growth-37.76%
EPS Diluted Growth-37.76%
Weighted Average Shares Growth2.77%
Weighted Average Shares Diluted Growth2.77%
Dividends per Share Growth0.62%
Operating Cash Flow Growth-19.05%
Free Cash Flow Growth-15.03%
10-Year Revenue Growth per Share244.29%
5-Year Revenue Growth per Share56.31%
3-Year Revenue Growth per Share30.50%
10-Year Operating CF Growth per Share180.57%
5-Year Operating CF Growth per Share8.89%
3-Year Operating CF Growth per Share26.43%
10-Year Net Income Growth per Share-2.14%
5-Year Net Income Growth per Share-17.09%
3-Year Net Income Growth per Share-37.76%
10-Year Shareholders Equity Growth per Share147.71%
5-Year Shareholders Equity Growth per Share53.63%
3-Year Shareholders Equity Growth per Share17.97%
10-Year Dividend per Share Growth per Share153.72%
5-Year Dividend per Share Growth per Share30.10%
3-Year Dividend per Share Growth per Share27.84%
Receivables Growth-7.69%
Inventory Growth9.52%
Asset Growth5.88%
Book Value per Share Growth-0.29%
Debt Growth16.07%
R&D Expense Growth1.02%
SGA Expenses Growth7.16%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 62,716,335,481.513, captures the company's total value, considering both debt and equity. Income quality, 1.18, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.03, gauges operational efficiency, while the research and development to revenue, 10.50%, highlights investment in innovation. The ratio of intangibles to total assets, 24.88%, indicates the value of non-physical assets, and capex to operating cash flow, -156.31%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value62,716,335,481.513
Income Quality1.18
Sales General and Administrative to Revenue0.03
Research and Development to Revenue10.50%
Intangibles to Total Assets24.88%
Capex to Operating Cash Flow-156.31%
Capex to Revenue-12.89%
Capex to Depreciation-179.98%
Stock-Based Compensation to Revenue0.09%
Graham Number18.47
Return on Tangible Assets2.80%
Graham Net Net-11.20
Working Capital34,985,411
Tangible Asset Value28,386,136,914
Net Current Asset Value-23,060,775,429
Invested Capital1
Average Receivables10,382,837,320.5
Average Payables6,221,829,882
Average Inventory7,210,100,080
Days Sales Outstanding88
Days Payables Outstanding104
Days of Inventory On Hand127
ROIC3.63%
ROE0.05%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 0.68, and the price to book ratio, 0.68, reflect the market's valuation relative to the company's book value. The price to sales ratio, 1.39, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -39.61, and price to operating cash flows, 9.05, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio0.68
Price to Book Ratio0.68
Price to Sales Ratio1.39
Price Cash Flow Ratio9.05
Price Earnings to Growth Ratio7.23
Enterprise Value Multiple7.07
Price Fair Value0.68
Price to Operating Cash Flow Ratio9.05
Price to Free Cash Flows Ratio-39.61
Price to Tangible Book Ratio0.90
Enterprise Value to Sales1.51
Enterprise Value Over EBITDA7.51
EV to Operating Cash Flow18.37
Earnings Yield5.78%
Free Cash Flow Yield-4.65%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK) on the HKSE in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 15.575 in 2024.

What is the ticker symbol of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. stock?

The ticker symbol of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. stock is 2196.HK.

What is company IPO date?

IPO date of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is 2012-10-30.

What is company current share price?

Current share price is 13.280 HKD.

What is stock market cap today?

The market cap of stock today is 63714501109.000.

What is PEG ratio in 2024?

The current 7.227 is 7.227 in 2024.

What is the number of employees in 2024?

In 2024 the company has 40370.